Parasetamol ve kodein ve Doksilamin ve piridoksin etkileşimi
Parasetamol ve kodein ve Doksilamin ve piridoksin: her iki reçeteleme etiketi de bu kombinasyonu kontrendikasyon, kutulu uyarı veya kaçınma talimatı gibi en güçlü ifadelerle işaretliyor.
Reçeteyi yazan hekimin yönlendirmesi olmadan birlikte kullanmayın. Aşağıdaki etiket ifadeleri, FDA'nın kullandığı en güçlü ifadelerdir.
FDA etiketleri ne diyor
Kaynak: Parasetamol ve kodein (ACETAMINOPHEN AND CODEINE PHOSPHATE) etiketi · yürürlük tarihi 2026-01-22
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing of acetaminophen and codeine phosphate tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate ( see PRECAUTIONS, Drug Interactions ).
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of acetaminophen and codeine phosphate tablets with benzodiazepines and/or other CNS depressants, including alcohol [e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle…
Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs ( see PRECAUTIONS, Drug Interactions and Information for Patients/Caregivers ).
Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics ( see PRECAUTIONS, Drug Interactions ).
Kaynak: Doksilamin ve piridoksin (Doxylamine succinate and pyridoxine hydrochloride) etiketi · yürürlük tarihi 2025-12-03
Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 )
Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets use is not recommended if a woman is concurrently using central nervous system (CNS) depressants including alcohol.
Interference with urine drug screen: Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may interfere with urine screening for methadone, opiates and PCP ( 5.3 )
Interference with Urine Screen for Methadone, Opiates and Phencyclidine Phosphate (PCP) There have been reports of false positive urine screening tests for methadone, opiates, and PCP with doxylamine succinate/pyridoxine hydrochloride use [see Drug Interactions (7.3)].
Concurrent use of alcohol and other CNS depressants (such as hypnotic sedatives and tranquilizers) with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is not recommended.
Bu ikisinden fazlasını mı kullanıyorsunuz? Etkileşimler üst üste biner. Tüm listenizi tek seferde kontrol edin; liste tarayıcınızda kalır.
Sorgulama aracında açTıbbi tavsiye değildir. Interaction Checker, FDA etiket metinlerini ve NIH bilgi sayfalarını alıntılar. Bir etkileşimin sizin için önemli olup olmadığı dozlara, zamanlamaya, böbrek ve karaciğer fonksiyonuna ve diğer sağlık durumlarına bağlıdır. Bir eczacıya veya reçeteyi yazan hekime danışarak doğrulayın.